Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab withdrawal study in adults with CIDP
jRCT2041220037Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Nipocalimab with Placebo comparator (2 arms). Primary endpoint: Stage B: Time to first occurrence of a relapse event. Started Dec 2022; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCT2041220037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220037.